IR Portal for Topotarget
OMX Copenhagen: TOPO.CO
Seneste Kurs: 3,00
0,00
Branche: Sundhed
RESSOURCER
14/3 2012Webcast 2011 annual report 
18/11 2011Q3 2011 webcast
20/9 2011ProInvestor Life Science Seminar
18/11 2011Q3 2011 webcast
20/9 2011ProInvestor Life Science Seminar
27/3 2012Life Science Investment day Scandinavia
27/3 2012ProInvestor Life Scince Seminar
20/3 2012Shareholder meeting, Århus
27/3 2012ProInvestor Life Scince Seminar
20/3 2012Shareholder meeting, Århus
Senest opdateret 14/4 2012
VIRKSOMHEDSBESKRIVELSE:
Topotarget (NASDAQ OMX: TOPO.CO) is a Scandinavian-based international biotech company headquartered in Denmark, dedicated to improve cancer therapies. In collaboration with Spectrum Pharmaceuticals Inc. Topotarget currently focuses on the development in pivotal studies of its lead drug candidate, belinostat, which has demonstrated a clear anti-neoplastic effect in both hematological malignancies and solid tumors.
Belinostat can be used in combination with full doses of chemotherapy, and is currently in a pivotal trial within PTCL (peripheral T-cell lymphoma) and phase II in cancer of unknown primary site (CUP).
Topotarget’s cancer drug target is HDAC. Totect® is a product on the market developed from Topotarget’s drug discovery technology. Totect® is marketed by the company’s own sales specialists in the US. The European rights to Savene® were divested in March 2010 as a consequence of the focus to develop and commercialize belinostat.
For more information, please refer to www.topotarget.com.
Belinostat can be used in combination with full doses of chemotherapy, and is currently in a pivotal trial within PTCL (peripheral T-cell lymphoma) and phase II in cancer of unknown primary site (CUP).
Topotarget’s cancer drug target is HDAC. Totect® is a product on the market developed from Topotarget’s drug discovery technology. Totect® is marketed by the company’s own sales specialists in the US. The European rights to Savene® were divested in March 2010 as a consequence of the focus to develop and commercialize belinostat.
For more information, please refer to www.topotarget.com.
INVESTOR RELATIONS KONTAKT
CFO
e-mail:
Senest opdateret 19/1 2012
FINANSIELLE TAL
| 2011 | 2010 | 2009 | |
| Revenue | 65.598 | 129.038 | 43.979 |
| Research and development costs | -54.345 | -71.608 | -89.884 |
| Write down of R&D projects | 0.00 | -189.541 | -21.200 |
| Administrative expenses | -40.765 | -57.876 | -55.262 |
| Operating profit (EBIT) | -31.352 | -168.447 | -132.492 |
| Net financial items | 1.087 | 68.773 | -10.250 |
| Net profit/loss for the year | -33.011 | -55.689 | -140.464 |
| Capital resources ultimo | 114.302 | 205.068 | 130.145 |
| Total assets | 370.446 | 465.824 | 585.413 |
| Shareholder equity | 330.729 | 360.219 | 411.798 |
| Total number of shares in thousands | 132.652 | 132.652 | 132.609 |
| EPS | -0,25 | -0,42 | -1,06 |
| BVPS | 2,49 | 2,70 | 3,10 |
| Average number of employees | 42 | 50 | 58 |
Senest opdateret 14/4 2012
Topotarget expects an estimated pre-tax loss in the range of DKK 75-95 million
Forventet: 2012
Forventet: 2012
The expected net cash and cash equivalents will be around DKK 35-55 million at yearend 2012
Forventet: 2012
Forventet: 2012
Belinostat: Phase 2 CUP data
Forventet: 2012
Forventet: 2012
Belinostat: Pivotal PTCL data
Forventet: 2012
Forventet: 2012
Senest opdateret 26/4 2012
Edison Investment Research Limited
Mick Cooper
Mick Cooper
Danske Bank
Thomas Bowers
Thomas Bowers
Senest opdateret 2/8 2011
Francois Martelet
CEO
Axel Mescheder
Chief Medical & Development Officer
Anders Fink Vadsholt
CFO
Inge Holm Lauritzen
VP Business Development & Licensing/Strategic Planning
Senest opdateret 8/9 2011
Senest opdateret 14/3 2012
Aktiekurs for Topotarget
Du skal opdatere din Flash Player for at se dette indhold
DINE MULIGHEDER
| Dit kursmål: ingen |
| Gennemsnitligt kursmål (AVG): 3,00 (6) |
| Hvor vil Topotarget lukke fra deres nuværende pris? Over  eller under  den nuværende kurs? |
|||
| Om en måned |
Om tre måneder |
Om seks måneder |
Om et år |
|
Brugernes anbefaling
SALG
KØB
|
|||
SKRIV INDLÆG
saving..
;){kind=link}